摘要
目前治疗骨质疏松症的药物仍以抗骨吸收药物为主,作用途径比较单一、作用效果也有限。特立帕肽为人甲状旁腺激素类似物,具有与天然甲状旁腺激素(PTH)N端34个氨基酸序列相同的结构,它可以与PTH-1受体结合,发挥PTH对骨骼与肾脏的生理作用;同时不存在C端肽对骨代谢的不利影响。研究表明该药可以促进骨形成,增加骨密度,降低骨折风险,并可与其他治疗骨质疏松症药物联合应用增强疗效。该药2002年获美国FDA批准上市。本文就该药在骨质疏松症治疗中的应用作一综述。
Mechanism of anti-osteoporosis drugs has been focused on anti-bone absorption with the characteristics of single pharmacological pathway and limited effects. Teriparatide is the analogue of human parathyroid hormene（PTH） which contains same 34 amino acids segments at N-terminal compared with natural PTH. Teriparatide can make physiological effects like PTH without the side effect on bone metabolism. Research has proved that teriparatide can promote hone formation, increase bone density, decrease the risk of fracture and enhance its pharmaeologieal effects after its coadministration with other anti-osteoporosis drugs. Teriparatide has been used since 2002 with FDA approval. The article is a review of the application progress of teriparatide in treatment of osteoporosis.
出处
《国际药学研究杂志》
CAS
2008年第6期415-418,424,共5页
Journal of International Pharmaceutical Research
